Does the media favor FBIO or SGMO?

In the previous week, Fortress Biotech and Fortress Biotech both had 1 articles in the media. Fortress Biotech's average media sentiment score of 0.75 beat Sangamo Therapeutics' score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DOMH or SGMO?

Sangamo Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75

Is DOMH or SGMO more profitable?

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dominari -31.37% -206.20% -155.26% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Is CRIS or SGMO more profitable?

Curis has a net margin of -80.29% compared to Sangamo Therapeutics' net margin of -310.81%. Curis' return on equity of 0.00% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Does the media refer more to CRIS or SGMO?

In the previous week, Curis had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Curis and 1 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 beat Curis' score of -0.15 indicating that Sangamo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SGMO or AMGN more profitable?

Amgen has a net margin of 20.96% compared to Sangamo Therapeutics' net margin of -310.81%. Amgen's return on equity of 137.41% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% Amgen 20.96% 137.41% 13.28%

Does the media refer more to SGMO or AMGN?

In the previous week, Amgen had 43 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 44 mentions for Amgen and 1 mentions for Sangamo Therapeutics. Amgen's average media sentiment score of 1.14 beat Sangamo Therapeutics' score of 0.00 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amgen 32 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Sangamo Therapeutics (SGMO) Competitors

$0.07 0.00 (0.00%)

As of 07/8/2026

Compare

SGMO vs. FBIO, DOMH, CRIS, BOLT, and AMGN

Should you buy Sangamo Therapeutics stock or one of its competitors? MarketBeat compares Sangamo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sangamo Therapeutics include Fortress Biotech (FBIO), Dominari (DOMH), Curis (CRIS), Bolt Biotherapeutics (BOLT), and Amgen (AMGN). These companies are all part of the "biotechnology" industry.

How does Sangamo Therapeutics compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Fortress Biotech has a net margin of 193.12% compared to Sangamo Therapeutics' net margin of -310.81%. Fortress Biotech's return on equity of 109.66% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Fortress Biotech has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.73	$6.82M	$3.17	1.04
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Fortress Biotech currently has a consensus target price of $17.00, suggesting a potential upside of 416.72%. Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Fortress Biotech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

In the previous week, Fortress Biotech and Fortress Biotech both had 1 articles in the media. Fortress Biotech's average media sentiment score of 0.75 beat Sangamo Therapeutics' score of 0.00 indicating that Fortress Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fortress Biotech beats Sangamo Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Dominari?

Dominari (NASDAQ:DOMH) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Dominari has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

42.5% of Dominari shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 55.3% of Dominari shares are held by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Dominari has higher revenue and earnings than Sangamo Therapeutics. Dominari is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.54	-$22.43M	-$4.03	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Sangamo Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Sangamo Therapeutics had 1 more articles in the media than Dominari. MarketBeat recorded 1 mentions for Sangamo Therapeutics and 0 mentions for Dominari. Dominari's average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Dominari	Neutral
Sangamo Therapeutics	Neutral

Summary

Sangamo Therapeutics beats Dominari on 10 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Curis?

Curis (NASDAQ:CRIS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

30.0% of Curis shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 5.8% of Curis shares are held by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Curis presently has a consensus price target of $340.00, suggesting a potential upside of 6,754.84%. Sangamo Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Curis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Curis has a net margin of -80.29% compared to Sangamo Therapeutics' net margin of -310.81%. Curis' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Curis has higher earnings, but lower revenue than Sangamo Therapeutics. Curis is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$7.06M	1.37	-$7.58M	-$23.80	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Curis has a beta of 3.08, suggesting that its stock price is 208% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

In the previous week, Curis had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Curis and 1 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 beat Curis' score of -0.15 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sangamo Therapeutics beats Curis on 8 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Bolt Biotherapeutics?

Bolt Biotherapeutics (NASDAQ:BOLT) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Sangamo Therapeutics has a net margin of -310.81% compared to Bolt Biotherapeutics' net margin of -455.15%. Bolt Biotherapeutics' return on equity of -100.89% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Sangamo Therapeutics had 1 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 1 mentions for Sangamo Therapeutics and 0 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Bolt Biotherapeutics	Neutral
Sangamo Therapeutics	Neutral

Bolt Biotherapeutics has higher earnings, but lower revenue than Sangamo Therapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.33	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Bolt Biotherapeutics presently has a consensus target price of $34.67, suggesting a potential upside of 771.02%. Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Bolt Biotherapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Summary

Bolt Biotherapeutics beats Sangamo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Amgen?

Sangamo Therapeutics (NASDAQ:SGMO) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Amgen had 43 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 44 mentions for Amgen and 1 mentions for Sangamo Therapeutics. Amgen's average media sentiment score of 1.14 beat Sangamo Therapeutics' score of 0.00 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amgen	32 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Amgen has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Amgen	$36.75B	5.34	$7.71B	$14.37	25.30

Amgen has a net margin of 20.96% compared to Sangamo Therapeutics' net margin of -310.81%. Amgen's return on equity of 137.41% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Amgen	20.96%	137.41%	13.28%

Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Amgen has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Sangamo Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Amgen has a consensus target price of $355.73, suggesting a potential downside of 2.17%. Given Sangamo Therapeutics' higher possible upside, equities analysts plainly believe Sangamo Therapeutics is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

Summary

Amgen beats Sangamo Therapeutics on 14 of the 17 factors compared between the two stocks.

Get Sangamo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMO vs. The Competition

Export

Metric	Sangamo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.66M	$3.78B	$6.93B	$12.49B
Dividend Yield	N/A	2.18%	2.68%	7.79%
P/E Ratio	-0.17	21.70	27.35	24.62
Price / Sales	0.78	328.99	549.66	113.75
Price / Cash	N/A	145.39	48.45	59.17
Price / Book	-1.85	8.62	11.02	6.46
Net Income	-$122.93M	$23.85M	$3.57B	$331.60M
7 Day Performance	N/A	0.96%	0.42%	0.33%
1 Month Performance	N/A	13.39%	6.55%	2.51%
1 Year Performance	N/A	55.25%	29.66%	21.59%

Sangamo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMO Sangamo Therapeutics	1.2317 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
FBIO Fortress Biotech	2.3704 of 5 stars	$2.95 -3.0%	$17.00 +476.3%	+65.3%	$100.99M	$63.26M	0.93	170
DOMH Dominari	0.3984 of 5 stars	$2.93 -0.3%	N/A	-41.2%	$66.49M	$123.10M	N/A	4
CRIS Curis	3.4245 of 5 stars	$5.94 -14.3%	$17.00 +186.2%	-86.4%	$13.51M	$9.44M	N/A	60	Gap Down
BOLT Bolt Biotherapeutics	2.3162 of 5 stars	$4.01 -1.0%	$34.67 +764.5%	-36.0%	$7.78M	$7.70M	N/A	90	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMO) was last updated on 7/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. FBIO, DOMH, CRIS, BOLT, and AMGN

How does Sangamo Therapeutics compare to Fortress Biotech?

Summary

How does Sangamo Therapeutics compare to Dominari?

Summary

How does Sangamo Therapeutics compare to Curis?

Summary

How does Sangamo Therapeutics compare to Bolt Biotherapeutics?

Summary

How does Sangamo Therapeutics compare to Amgen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. FBIO, DOMH, CRIS, BOLT, and AMGN

How does Sangamo Therapeutics compare to Fortress Biotech?

Do institutionals & insiders hold more shares of FBIO or SGMO?

Is FBIO or SGMO more profitable?

Which has better valuation and earnings, FBIO or SGMO?

Do analysts rate FBIO or SGMO?

Which has more risk & volatility, FBIO or SGMO?

Does the media favor FBIO or SGMO?

Summary

How does Sangamo Therapeutics compare to Dominari?

Which has more volatility & risk, DOMH or SGMO?

Do institutionals & insiders hold more shares of DOMH or SGMO?

Is DOMH or SGMO more profitable?

Which has higher valuation and earnings, DOMH or SGMO?

Do analysts prefer DOMH or SGMO?

Does the media favor DOMH or SGMO?

Summary

How does Sangamo Therapeutics compare to Curis?

Do institutionals & insiders hold more shares of CRIS or SGMO?

Do analysts rate CRIS or SGMO?

Is CRIS or SGMO more profitable?

Which has stronger valuation & earnings, CRIS or SGMO?

Which has more risk & volatility, CRIS or SGMO?

Does the media refer more to CRIS or SGMO?

Summary

How does Sangamo Therapeutics compare to Bolt Biotherapeutics?

Is BOLT or SGMO more profitable?

Do insiders & institutionals have more ownership in BOLT or SGMO?

Does the media favor BOLT or SGMO?

Which has higher valuation & earnings, BOLT or SGMO?

Do analysts recommend BOLT or SGMO?

Which has more volatility and risk, BOLT or SGMO?

Summary

How does Sangamo Therapeutics compare to Amgen?

Does the media refer more to SGMO or AMGN?

Do insiders and institutionals have more ownership in SGMO or AMGN?

Which has preferable valuation & earnings, SGMO or AMGN?

Is SGMO or AMGN more profitable?

Which has more risk and volatility, SGMO or AMGN?

Do analysts recommend SGMO or AMGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools